沙巍 主任医师，教授
硕士招生类型：学术型；专业型
硕士招生专业：内科学（呼吸内科学）
博士招生类型：学术型；专业型
博士招生专业：内科学（呼吸内科学）
所在院系：附属肺科医院
联系方式：shfksw@126.com/**
课题组链接：
研究方向
主要任职
科研业绩

结核病临床诊治及相关基础研究 Diagnosis and treatment of tuberculosis
中华医学会结核病学分会常务委员Member of the Standing Committee, Chinese Society for Tuberculosis，Chinese Medical Association;
中国防痨协会常务理事Executive member, Chinese Antituberculosis Association;
上海医学会结核病学分会主任委员Chairman, Society for Tuberculosis, Shanghai Medical Association;
中国防痨协会非结核分枝杆菌病分会主任委员Chairman, Society for Nontuberculosis mycobacteria, Chinese Antituberculosis Association;
中国医促会结核病学分会常务委员Member of the Standing Committee, China Promotive Association for Medical;
中国防痨协会临床分会常务委员Member of the Standing Committee, Society for Clinical, Chinese Antituberculosis Association;
上海市防痨协会副理事长Vice director, Shanghai Antituberculosis Association;
《中国防痨杂志》副主编Deputy editor of Chinese Journal of Anti-tuberculosis.
（1）对结核病开展精准诊治策略的基础和临床研究：采用高通量多组学方法，对结核病患者外周血及其它标本进行新的生物标志物的筛查并通过临床研究进行论证；basic and clinical research on the accurate diagnosis and treatment of tuberculosis: find out new biomarkers in peripheral blood or alternative specimens then confirm the significance by the high-throughput and multi-omics approach;
（2）对耐药结核病患者的免疫特征进行研究，为免疫治疗和细胞治疗奠定基础；Focus on the immune characteristics of drug resistant tuberculosis providing further reference for immunotherapy and cell therapy;
（3）对非结核分枝杆菌病进行遗传易感性的相关研究;access the genetic susceptibility to the nontuberculosis mycobacteria;
（4）结核病优化新方案的研究：包括对复治结核病、耐药结核病和初治菌阳肺结核患者进行多中心、大样本量缩短疗程新方案的研究，抗结核新药的新药评价等。Research on optimize the new treatment of tuberculosis: including multicenter clinical study on follow-up and promotion of medium-long-term efficacy of new treatment for retreated drug resistant and primary positive pulmonary tuberculosis, evaluate the new antituberculotic and so on.
目前主持国家十三五重大专项，上海市感染性疾病（结核病）临床医学研究中心、上海市临床重点专科（结核病科）、申康三年行动计划重大项目等科研项目，入选上海市医学领军人才，在研经费4千余万元。
Dr. Sha is taking charge of projects in the national science and technology pillar program during the thirteenth five-year plan period, director of Shanghai Infectious Diseases (Tuberculosis) Clinical Medical Research Center, key clinical department (tuberculosis) of Shanghai, three-year of action plan of Shanghai Shenkang Hospital Development Center and so on. Being selected as leading talents of medicine in Shanghai and her research team is running 40 million research funds.
参与制订国家级指南十余部，主编专著2部，发表论文80余篇，荣获省部级科技进步奖2项，发明专利1项，在缩短初治敏感肺结核疗程、提高复治肺结核治愈率、耐多药患者综合治疗、非结核分枝杆菌病的诊治新技术研究中均有突出贡献。
Participated in the formulation of more than 10 national guidelines, edited 2 monographs, published more than 80 papers, won the provincial and ministerial level scientific and technological progress award 2, invention patent 1, and has made outstanding contributions in shortening the course of treatment of primary sensitive pulmonary tuberculosis, improving the cure rate of re-treatment of pulmonary tuberculosis, multi-drug resistant patients comprehensive treatment, non-tuberculosis mycosis diagnosis and treatment of new technologies.